Corning Jereh's first phase III study of PD-L1/CTLA-4 double antibody successfully submitted a marketing application

Article source: Medical Cube Info

On March 31, Corning Jereh announced that the first phase III clinical study of the company's PD-L1/CTLA-4 dual antibody KN046 (study number: ENREACH-LUNG-01) successfully completed the first interim analysis and reached the preset endpoint

KN046 is the world's first PD-L1/CTLA-4 bispecific antibody independently developed by Corning Jereh.

ENREACH-LUNG-01 is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study of KN046 in combination with platinum-based chemotherapy in patients with advanced unresectable or metastatic squamous non-small cell lung cancer.

First interim analysis by the Independent Data Monitoring Committee (iDMC), KN046 plus platinum-based chemotherapy versus placebo plus Platinum chemotherapy resulted in a significant and clinically meaningful prolongation of progression-free survival (PFS) in patients with advanced squamous non-small cell lung cancer, meeting pre-specified superiority criteria

KN046 has carried out nearly 20 clinical trials at different stages covering more than 10 types of tumors, including non-small cell lung cancer, thymic cancer, pancreatic cancer, liver cancer, esophageal squamous cell carcinoma, and triple-negative breast cancer in Australia, the United States and China.